2020
Anti-Müllerian hormone as a qualitative marker - or just quantity?
Kotlyar A, Seifer DB. Anti-Müllerian hormone as a qualitative marker - or just quantity? Current Opinion In Obstetrics & Gynecology 2020, 32: 219-226. PMID: 32205525, DOI: 10.1097/gco.0000000000000623.Peer-Reviewed Original ResearchConceptsAnti-Müllerian hormoneOvarian reserve testingClinical pregnancy rateLive birth rateOnset of menopausePremature ovarian insufficiencyNumber of oocytesSignificant predictive valueAMH levelsFertilization cyclesPregnancy rateOvarian insufficiencyIntracycle variabilityOocyte qualityPredictive valueEarly folliclesFetal trisomiesHormoneReproductive technologiesRiskQualitative markersSmall interMenopauseInsufficiencyFollicles
2018
Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012–2013
Tal R, Seifer DB, Wantman E, Baker V, Tal O. Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012–2013. Fertility And Sterility 2018, 109: 258-265. PMID: 29331235, DOI: 10.1016/j.fertnstert.2017.10.021.Peer-Reviewed Original ResearchAdultAnti-Mullerian HormoneArea Under CurveBiomarkersChi-Square DistributionCryopreservationDatabases, FactualEmbryo TransferFemaleFertilization in VitroHumansInfertilityLive BirthLogistic ModelsMaleOdds RatioPregnancyPregnancy RateRetrospective StudiesRisk FactorsROC CurveSingle Embryo TransferTime FactorsTreatment Outcome
2017
Vitamin D Decreases Serum VEGF Correlating with Clinical Improvement in Vitamin D-Deficient Women with PCOS: A Randomized Placebo-Controlled Trial
Irani M, Seifer DB, Grazi RV, Irani S, Rosenwaks Z, Tal R. Vitamin D Decreases Serum VEGF Correlating with Clinical Improvement in Vitamin D-Deficient Women with PCOS: A Randomized Placebo-Controlled Trial. Nutrients 2017, 9: 334. PMID: 28350328, PMCID: PMC5409673, DOI: 10.3390/nu9040334.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeVascular endothelial growth factorOvarian hyperstimulation syndromeSerum VEGF levelsVitamin DVEGF levelsVitD supplementationVitD treatmentSeverity of OHSSSerum vascular endothelial growth factorRandomized placebo-controlled trialFerriman-Gallwey hirsutism scoreBeneficial effectsCharacteristic clinical abnormalitiesPlacebo-controlled trialVitamin D levelsVitamin D supplementationMultiple clinical parametersSignificant decreaseEndothelial growth factorD supplementationHirsutism scoreHyperstimulation syndromeVitD groupRandomized Placebo
2015
Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimüllerian hormone: a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012–2013
Seifer DB, Tal O, Wantman E, Edul P, Baker VL. Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimüllerian hormone: a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012–2013. Fertility And Sterility 2015, 105: 385-393.e3. PMID: 26515380, DOI: 10.1016/j.fertnstert.2015.10.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersCryopreservationDatabases, FactualEmbryo TransferFemaleFertilityFertilization in VitroHumansInfertilityLinear ModelsLive BirthLogistic ModelsMiddle AgedMultivariate AnalysisOocyte RetrievalPatient SelectionPregnancyPregnancy RatePregnancy, MultipleReproductive Techniques, AssistedRetrospective StudiesRisk AssessmentRisk FactorsTreatment OutcomeYoung AdultConceptsLive birth rateAntimüllerian hormoneCancellation rateAMH levelsAssisted Reproductive Technology Clinic Outcome Reporting System databaseAssisted reproduction technology (ART) outcomesEmbryo cryopreservation ratesSerum antimüllerian hormoneTotal cancellation rateMultiple birth ratesReporting System databaseCycle startAutologous cyclesClinical pregnancyCycle cancellationPrognostic factorsAMH valuesFresh cyclesCycle outcomePrognostic indicatorAMH concentrationsRetrospective analysisMAIN OUTCOMEEmbryo transferMultivariate analysisAssessing ovarian response: antral follicle count versus anti-Müllerian hormone
Fleming R, Seifer DB, Frattarelli JL, Ruman J. Assessing ovarian response: antral follicle count versus anti-Müllerian hormone. Reproductive BioMedicine Online 2015, 31: 486-496. PMID: 26283017, DOI: 10.1016/j.rbmo.2015.06.015.Peer-Reviewed Original ResearchConceptsAntral follicle countAnti-Müllerian hormoneAMH levelsOvarian reserveFollicle countOvarian responseFollicle numberPredictive valueSerum anti-Müllerian hormoneGood predictive valuePersonalization of treatmentGold standard biomarkerOvarian stimulationExogenous gonadotrophinsMenstrual cyclePoor responseHormone biomarkersOocyte numberUltrasound biomarkersBiomarkersAmerican SocietyGood responseSame ageHormoneStimulationPersonalized prediction of live birth: Are we there yet?
Seifer DB, Tal R. Personalized prediction of live birth: Are we there yet? Fertility And Sterility 2015, 104: 283-285. PMID: 26049289, DOI: 10.1016/j.fertnstert.2015.05.004.Peer-Reviewed Original Research
2014
Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis
Tal R, Tal O, Seifer BJ, Seifer DB. Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertility And Sterility 2014, 103: 119-130.e3. PMID: 25450298, DOI: 10.1016/j.fertnstert.2014.09.041.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEmbryo ImplantationFemaleFertilization in VitroHumansInfertility, FemaleMiddle AgedObservational Studies as TopicOvarian ReserveOvaryOvulation InductionPregnancyPregnancy OutcomePregnancy RatePrevalenceReproducibility of ResultsRisk FactorsSensitivity and SpecificityYoung AdultConceptsPredictor of implantationClinical pregnancy rateAntimüllerian hormoneClinical pregnancyOvarian reservePregnancy rateOdds ratioIVF/intracytoplasmic sperm injectionSystematic reviewSerum AMH levelsPolycystic ovary syndromeReproductive technologiesIntracytoplasmic sperm injectionNondonor cyclesAMH levelsOvary syndromeImplantation rateDiagnostic odds ratioObservational studyMAIN OUTCOMEClinical utilitySperm injectionPregnancyAssisted conceptionFertility treatmentCharacterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes
Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. American Journal Of Obstetrics And Gynecology 2014, 211: 59.e1-59.e8. PMID: 24593938, DOI: 10.1016/j.ajog.2014.02.026.Peer-Reviewed Original ResearchConceptsSerum antimüllerian hormone levelsAntimüllerian hormone levelsClinical pregnancy ratePopulation of womenAMH levelsPregnancy rateHormone levelsHigher clinical pregnancy rateElevated AMH levelsPresence of amenorrheaMultiple pregnancy rateOvarian hyperstimulation syndromeRetrospective cohort studyHigher AMH levelsPolycystic ovarian morphologyPolycystic ovarian syndromeSyndrome phenotypeReproductive technology outcomesHyperstimulation syndromePCOS severityClinical pregnancyOvarian stimulationTotal testosteroneCohort studyOvarian syndrome
2013
Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone
Toner JP, Seifer DB. Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone. Fertility And Sterility 2013, 99: 1825-1830. PMID: 23548941, DOI: 10.1016/j.fertnstert.2013.03.001.Peer-Reviewed Original Research
2012
Anti-Müllerian hormone as an independent predictor of twin versus singleton pregnancy in fresh cycles
Tal R, Seifer DB, Khanimov M, Schwartz E, Grazi RV, Malter HE. Anti-Müllerian hormone as an independent predictor of twin versus singleton pregnancy in fresh cycles. Reproductive BioMedicine Online 2012, 26: 360-367. PMID: 23419793, DOI: 10.1016/j.rbmo.2012.12.002.Peer-Reviewed Original ResearchConceptsAnti-Müllerian hormoneSerum AMH concentrationsFresh non-donor cyclesSerum anti-Müllerian hormoneNon-donor cyclesTwin pregnanciesAMH concentrationsSingleton pregnanciesIndependent predictorsIncidence of twinsFresh cyclesMultiple pregnanciesFertility clinicsPossible predictorsEgg reserveQuantitative ovarian responseLive birth rateChance of pregnancyROC curve analysisSignificant predictive abilityMultiple gestationsOvarian responseTwin gestationsRetrospective studyPregnancy rate
2011
Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with normal ovarian reserve
Buyuk E, Seifer DB, Illions E, Grazi RV, Lieman H. Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with normal ovarian reserve. Fertility And Sterility 2011, 95: 2364-2368. PMID: 21529798, DOI: 10.1016/j.fertnstert.2011.03.081.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersBody Mass IndexCross-Sectional StudiesDown-RegulationFemaleFollicle Stimulating Hormone, HumanHumansInfertility, FemaleLinear ModelsNew YorkOocyte RetrievalOverweightOvulationOvulation InductionReproductive Techniques, AssistedRisk AssessmentRisk FactorsConceptsElevated body mass indexNormal ovarian reserveBody mass indexSerum AMH levelsOvarian reserveNumber of oocytesAMH levelsObese womenInfertile womenMass indexHormone levelsDay 3 serum FSH levelsSerum anti-Mullerian hormone (AMH) levelsAnti-Mullerian hormone levelsLow serum AMH levelsSerum antimullerian hormone (AMH) levelsNormal body mass indexAntimullerian hormone levelsReproductive technology cyclesSerum FSH levelsDiminished ovarian reserveIU/L.Cross-sectional studyOvarian hyperstimulationIVF cyclesRandom anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels
Buyuk E, Seifer DB, Younger J, Grazi RV, Lieman H. Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels. Fertility And Sterility 2011, 95: 2369-2372. PMID: 21497340, DOI: 10.1016/j.fertnstert.2011.03.071.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersChi-Square DistributionEmbryo TransferFemaleFertilization in VitroFollicle Stimulating Hormone, HumanFollicular PhaseHumansInfertility, FemaleNew YorkOocyte RetrievalOvulationOvulation InductionPregnancyPregnancy RateRetrospective StudiesTime FactorsTreatment OutcomeUp-RegulationConceptsAnti-Müllerian hormoneNumber of oocytesClinical pregnancy rateSerum AMH levelsDiminished ovarian reserveAMH levelsFSH levelsDay 3 embryosElevated FSHOvarian responseART cyclesPregnancy rateEarly follicular FSH levelsFollicle-stimulating hormone levelsSerum anti-Müllerian hormoneCycle cancellation rateSerum FSH levelsReproductive technology programCycle cancellationOvarian reserveRetrospective studyHormone levelsMAIN OUTCOMECancellation rateRandom sera
2008
Plasma brain-derived neurotrophic factor in women after bariatric surgery: a pilot study
Merhi ZO, Minkoff H, Lambert-Messerlian GM, Macura J, Feldman J, Seifer DB. Plasma brain-derived neurotrophic factor in women after bariatric surgery: a pilot study. Fertility And Sterility 2008, 91: 1544-1548. PMID: 18950757, DOI: 10.1016/j.fertnstert.2008.09.032.Peer-Reviewed Original Research
2007
Biologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in women
Seifer DB, Golub ET, Lambert-Messerlian G, Springer G, Holman S, Moxley M, Cejtin H, Nathwani N, Anastos K, Minkoff H, Greenblatt RM. Biologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in women. Fertility And Sterility 2007, 88: 1645-1652. PMID: 17418155, PMCID: PMC2682326, DOI: 10.1016/j.fertnstert.2007.01.122.Peer-Reviewed Original ResearchConceptsWomen's Interagency HIV StudyEarly follicular phaseOvarian reserveInhibin BHIV infectionMIS levelsFollicular phaseHIV StudyLower inhibin B levelsReproductive agingSerum samplesHIV infection influencesInhibin B levelsMulticenter prospective studyCross-sectional studyMenstrual cycle phaseCycle phaseUninfected womenCohort studyFSH levelsMenstrual bleedingNegative womenHIV serostatusSerum markersProspective study
2004
Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol
Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertility And Sterility 2004, 82: 1323-1329. PMID: 15533354, DOI: 10.1016/j.fertnstert.2004.03.061.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEstradiolFemaleFertilization in VitroFollicle Stimulating HormoneGlycoproteinsHumansInhibinsMultivariate AnalysisOsmolar ConcentrationOvulation InductionPredictive Value of TestsPregnancyPregnancy RateRetrospective StudiesTesticular HormonesTime FactorsTreatment OutcomeConceptsReproductive technology outcomesMullerian-inhibiting substanceYears of ageMultivariate regression analysisInhibin BPregnancy outcomesIVF outcomesAntimullerian hormoneHigher clinical pregnancy rateSerum samplesAvailable serum markersDay 3 FSHSerum antimullerian hormoneClinical pregnancy rateClinical pregnancy outcomesInhibin B levelsFollicle-stimulating hormoneConsecutive serum samplesMüllerian-inhibiting substanceGreater prognostic valueTechnology outcomesRegression analysisClinical pregnancyOvarian stimulationOvulation inductionImpact of retained embryos on the outcome of assisted reproductive technologies
Lee HC, Seifer DB, Shelden RM. Impact of retained embryos on the outcome of assisted reproductive technologies. Fertility And Sterility 2004, 82: 334-337. PMID: 15302280, DOI: 10.1016/j.fertnstert.2004.01.035.Peer-Reviewed Original ResearchConceptsEmbryo transfer cyclesPregnancy outcomesEmbryo transferTransfer cyclesTransfer catheterInitial embryo transferEmbryo transfer catheterAssisted reproductive technology practiceRetained embryosOocyte retrievalImplantation rateDelivery ratePregnancy rateRetrospective analysisMAIN OUTCOMEReproductive technology practiceEmbryo cyclesUse of ultrasoundCatheterAdverse effectsFertilization programFrozen embryosReproductive technologiesOutcomesEmbryo retention
2000
Progesterone, Inhibin, and hCG Multiple Marker Strategy to Differentiate Viable From Nonviable Pregnancies
PHIPPS M, HOGAN J, PEIPERT J, LAMBERT-MESSERLIAN G, CANICK J, SEIFER D. Progesterone, Inhibin, and hCG Multiple Marker Strategy to Differentiate Viable From Nonviable Pregnancies. Obstetrics And Gynecology 2000, 95: 227-231. DOI: 10.1097/00006250-200002000-00011.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkersChorionic GonadotropinChorionic Gonadotropin, beta Subunit, HumanCohort StudiesFemaleFetal ViabilityHumansInhibinsPredictive Value of TestsPregnancyPregnancy ComplicationsPregnancy OutcomePregnancy Trimester, FirstProgesteroneProspective StudiesROC CurveSensitivity and SpecificityConceptsDual-biomarker strategyMultiple biomarker strategyNonviable pregnanciesSerum progesteroneBiomarker strategiesComplaints of painProspective cohort studySymptomatic pregnant womenCombination of progesteroneCohort studyCombination of serumInhibin AUrine biomarkersFirst trimesterPregnant womenEarly gestationNonviable outcomesPregnancySingle biomarkerHCGProgesteroneSpecific biomarkersDiagnostic accuracySerum samplesBiomarkersProgesterone, inhibin, and hCG multiple marker strategy to differentiate viable from nonviable pregnancies.
Phipps M, Hogan J, Peipert J, Lambert-Messerlian G, Canick J, Seifer D. Progesterone, inhibin, and hCG multiple marker strategy to differentiate viable from nonviable pregnancies. Obstetrics And Gynecology 2000, 95: 227-31. PMID: 10674584, DOI: 10.1016/s0029-7844(99)00480-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkersChorionic GonadotropinChorionic Gonadotropin, beta Subunit, HumanCohort StudiesFemaleFetal ViabilityHumansInhibinsPredictive Value of TestsPregnancyPregnancy ComplicationsPregnancy OutcomePregnancy Trimester, FirstProgesteroneProspective StudiesROC CurveSensitivity and SpecificityConceptsDual-biomarker strategyMultiple biomarker strategyNonviable pregnanciesSerum progesteroneBiomarker strategiesComplaints of painProspective cohort studySymptomatic pregnant womenCombination of progesteroneCohort studyCombination of serumInhibin AUrine biomarkersFirst trimesterPregnant womenEarly gestationNonviable outcomesPregnancySingle biomarkerHCGProgesteroneSpecific biomarkersDiagnostic accuracySerum samplesBiomarkers
1999
Diagnosis of acute and persistent ectopic pregnancy.
Graczykowski JW, Seifer DB. Diagnosis of acute and persistent ectopic pregnancy. Clinical Obstetrics & Gynecology 1999, 42: 9-22; quiz 55-6. PMID: 10073295, DOI: 10.1097/00003081-199903000-00005.Peer-Reviewed Original Research
1998
Elevated level of follicular fluid vascular endothelial growth factor is a marker of diminished pregnancy potential
Friedman C, Seifer D, Kennard E, Arbogast L, Alak B, Danforth D. Elevated level of follicular fluid vascular endothelial growth factor is a marker of diminished pregnancy potential. Fertility And Sterility 1998, 70: 836-839. PMID: 9806563, DOI: 10.1016/s0015-0282(98)00301-x.Peer-Reviewed Original ResearchConceptsFF VEGF concentrationsAmpules of gonadotropinsVEGF concentrationsClinical pregnancyChart reviewFollicular fluid vascular endothelial growth factorFollicular fluid vascular endothelial growth factor concentrationsDay 3 FSH levelsFollicular fluid VEGF concentrationsVascular endothelial growth factor concentrationsClinical pregnancy rateEstradiol serum concentrationsPeak estradiol levelsRetrospective chart reviewUniversity teaching centerVascular endothelial growth factorNumber of oocytesYears of ageEndothelial growth factorGrowth factor concentrationsFF VEGFSingle IVFFSH levelsPatient ageEstradiol levels